MAIN Medical imaging biz finds home
The diagnostic imaging arm of MAIN (Mid-Atlantic Imaging Network) Medical, a major network of freestanding medical imaging centers operating in the Mid-Atlantic region, has been acquired by a management and investment group. The group, which took
The diagnostic imaging arm of MAIN (Mid-Atlantic Imaging Network) Medical, a major network of freestanding medical imaging centers operating in the Mid-Atlantic region, has been acquired by a management and investment group. The group, which took ownership Aug. 16, is being led by MAIN's president and CEO, Anthony Geramita. Terms of the agreement have not been disclosed, but include acquisition of the five imaging centers, plus the Mobile Ultrasound Division, that the former company operated, as well as rights to the MAIN Medical name. The acquisition is a natural progression for MAIN Medical, according to Geramita, who has led the firm for the past two years. The Pittsburgh-based group plans to open more centers and develop partnerships with hospitals and other imaging providers in the region.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.